Overview

A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Status:
Completed

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-PCSSC in subjects with elevated LDL-C.

Phase:

Phase 1

Details

Lead Sponsor:

Alnylam Pharmaceuticals

Collaborator:

The Medicines Company